English, Article edition: Measuring Treatment Preferences and Willingness to Pay for Docetaxel in Advanced Ovarian Cancer George Dranitsaris; Julia Elia-Pacitti; Wayne Cottrell

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/93403
Physical Description
  • article
Language
  • English

Edition details

Title
  • Measuring Treatment Preferences and Willingness to Pay for Docetaxel in Advanced Ovarian Cancer
Author
  • George Dranitsaris
  • Julia Elia-Pacitti
  • Wayne Cottrell
Physical Description
  • article
Notes
  • Background: Docetaxel is an equally active alternative to paclitaxel in advanced ovarian cancer but has a different adverse effect profile. Whilst paclitaxel is associated with less haematological toxicity, such as febrile neutropenia and anaemia, docetaxel causes less sensory and motor neuropathy. Objective: To measure the economic value and preference scores for docetaxel as an alternative to paclitaxel in patients with advanced ovarian cancer. Design and setting: A cost-benefit analysis using a consumer-based willingness-to-pay (WTP) approach was conducted. The study population consisted of a patient surrogate sample comprised of 80 oncology pharmacists and nurses from eight Canadian provinces. Background information on ovarian cancer was provided including its current management, and differences in adverse effects between docetaxel and paclitaxel. Respondents were then asked what their preferred product would be if they were diagnosed with ovarian cancer and how much they would be willing to pay per cycle for six cycles in the form of a co-payment (i.e. user Study perspective: Canadian healthcare system perspective. Main outcome measures and results: The WTP survey instrument was simple to administer and easily understood by participants. Respondents ranked motor neuropathy as being the most unpleasant adverse effect of treatment. Of the sample, 63.8% preferred to use docetaxel instead of paclitaxel (p =​ 0.075). The patient surrogate sample was willing to pay a mean of 64 Canadian dollars ($Can; 2003 values) [95% CI $Can33, $Can92] per cycle for the benefits offered by docetaxel as an alternative to paclitaxel. This estimate was marginally lower than the incremental cost of $Can87 per cycle of docetaxel. Conclusion: A substantial portion of Canadian patients with ovarian cancer would likely prefer to be treated with docetaxel instead of paclitaxel for the management of their disease and would be willing to pay a portion of the incremental cost. Therefore, both options should be offered to patients, and selection of treatment can be based on reducing the risk of the toxicity that concerns the patient the most.
  • Cost-benefit, Docetaxel, Ovarian-cancer, Paclitaxel, Willingness-to-pay
  • RePEc:wkh:phecon:v:22:y:2004:i:6:p:375-387
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment